A Retrospective Chart Review Study of Gene-Eden-VIR/Novirin

Cytomegalovirus Infections Clinical Trial

Official title:

A Retrospective Chart Review Study of Gene-Eden-VIR/Novirin

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02715752
• Other study ID #: 022015
• Status: Completed
• Phase: N/A
• First received: March 17, 2016
• Last updated: April 24, 2016
• Start date: January 2016
• Est. completion date: March 2016

Study information

• Verified date: April 2016
• Source: The Center for the Biology of Chronic Disease
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Observational

Clinical Trial Summary

This study measured the changes in health-related complaints by analyzing charts of individuals, who are infected with a latent virus, who have used Gene-Eden-VIR/Novirin.

Description:

The medical community calls the movement from severe to mild disease and from mild to normal health, 'relieving symptoms', and the interventions that cause such movement, drugs, medications, or therapies. The alternative community calls the movement from normal health to superior health, 'boosting health' (or boosting the immune system, or improving your sex drive, or boosting any another well functioning physiological system), and the interventions that cause such movement, natural remedies, dietary supplements, complementary treatments, etc. In general, these interventions aim to achieve superior performance of a normal human body. Of course, boosting the body's normal performance improves many of its capabilities, such as higher resistance to diseases, faster recovery from fatigue, better mental concentration, etc. Each movement presents different objectives. Relieving symptoms represents the ability of an intervention to reduce the frequency, duration, and severity of a disease. In contrast, boosting health represents the ability of an intervention to increase the frequency, duration, and quality of a person's health. In the current study, the investigators would like to measure the changes in health-related complaints by analyzing charts of individuals, who are infected with latent virus, and who have used Gene-Eden-VIR/Novirin.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 1000
• Est. completion date: March 2016
• Est. primary completion date: March 2016
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Latent viral infection with either HSV, HPV, VZV, EBV, or CMV

• Taking Gene-Eden-VIR/Novirin

Exclusion Criteria:

• Use of other antiviral treatments

Study Design

Observational Model: Cohort, Time Perspective: Retrospective

Related Conditions & MeSH terms

• Communicable Diseases
• Cytomegalovirus Infections
• Epstein-Barr Virus Infections
• Herpes Simplex
• Herpes Simplex Infections
• Herpes Zoster
• Human Papillomavirus
• Infection
• Varicella-zoster Virus Infection
• Virus Diseases

Intervention

Dietary Supplement:
• Gene-Eden-VIR/Novirin

Locations

Country	Name	City	State
United States	The Center for the Biology of Chronic Disease	Valley Cottage	New York

Sponsors (1)

Lead Sponsor	Collaborator
The Center for the Biology of Chronic Disease

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	frequency of symptoms		one year	No
Primary	duration of symptoms		one year	No
Secondary	time to first recurrence		one year	No